Antibodies News and Research

RSS

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon.

26 Jun 2015

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

25 Jun 2015

UAlberta partnership could transform cancer treatment, improve patient outcomes

A multimillion dollar research partnership announced today at the University of Alberta is giving a "dream team" of researchers the opportunity to potentially transform cancer treatment and better patient outcomes.

25 Jun 2015

Novo Nordisk presents new data detailing the impact of hemophilia on patients, caregivers

Today, Novo Nordisk presented new data detailing the impact hemophilia has on both caregivers and those living with the disease.

From Novo Nordisk 25 Jun 2015

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America.

25 Jun 2015

New device tracks chemical messages that regulate cell growth

Biomedical engineers at the University of Toronto have invented a new device that more quickly and accurately "listens in" on the chemical messages that tell our cells how to multiply.

25 Jun 2015

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.

24 Jun 2015

PROMISSE study: Most women with lupus can expect good pregnancy outcomes

One of the most important and anxiety-producing concerns among patients with lupus is whether it is safe to become pregnant. A pioneering study led by researchers at Hospital for Special Surgery has shown that most women can expect a good pregnancy outcome if their lupus is inactive and they are free of certain risk factors.

23 Jun 2015

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy.

22 Jun 2015

Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

Vaxil Bio, a company specializing in the development of immunotherapy-based drugs, reports today that its lead product, ImMucin, has been granted an "orphan drug" designation by the US Food and Drug Administration, for the treatment of multiple myeloma (MM).

22 Jun 2015

Experimental vaccine candidate can stimulate immune system activity to prevent HIV infection

New research led by scientists at The Scripps Research Institute (TSRI), International AIDS Vaccine Initiative (IAVI) and The Rockefeller University shows in mice that an experimental vaccine candidate designed at TSRI can stimulate the immune system activity necessary to stop HIV infection. The findings could provide key information for the development of an effective AIDS vaccine.

22 Jun 2015

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Three studies describe advances toward development of antibodies to stop HIV

A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.

19 Jun 2015

Sequence of immunizations could be the promising route to HIV vaccine

The secret to preventing HIV infection lies within the human immune system, but the more-than-25-year search has so far failed to yield a vaccine capable of training the body to neutralize the ever-changing virus. New research from The Rockefeller University, and collaborating institutions, suggests no single shot will ever do the trick. Instead, the scientists find, a sequence of immunizations might be the most promising route to an HIV vaccine.

19 Jun 2015

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

Experimental AIDS vaccine candidate stimulates immune system to block infection in animal model

New research led by scientists at The Scripps Research Institute, International AIDS Vaccine Initiative and The Rockefeller University shows that an experimental vaccine candidate can stimulate the immune system to block HIV infection in mice.

18 Jun 2015

IDIBELL and IDIPAZ scientists identify epigenetic alterations in CVID

Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute and La Paz Hospital have identified epigenetic alterations in Common Variable Immunodeficiency (CVID), the most common primary immunodeficiency, using as a starting point genetically identical monozygotic twins discordant for the disease.

18 Jun 2015

Ragweed pollen can trigger strong allergic reactions

Ragweed (Ambrosia artemisiifolia) - an otherwise unremarkable plant - produces pollen that can trigger strong allergic reactions such as asthma even in very small quantities. Scientists from Technische Universität München (TUM) and Helmholtz Zentrum München have now published a joint study showing that the substance previously identified as the major allergen only induces such a vigorous allergic response in combination with the adenosine also present in the pollen.

18 Jun 2015

Antibodies News and Research

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

UC Santa Barbara professor develops novel therapeutic strategy for PKD

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

UAlberta partnership could transform cancer treatment, improve patient outcomes

Novo Nordisk presents new data detailing the impact of hemophilia on patients, caregivers

Larrea Biosciences merged into Gordian Holdings

New device tracks chemical messages that regulate cell growth

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

PROMISSE study: Most women with lupus can expect good pregnancy outcomes

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Vaxil's ImMucin receives FDA orphan drug designation for treatment of multiple myeloma

Experimental vaccine candidate can stimulate immune system activity to prevent HIV infection

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Three studies describe advances toward development of antibodies to stop HIV

Sequence of immunizations could be the promising route to HIV vaccine

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Experimental AIDS vaccine candidate stimulates immune system to block infection in animal model

IDIBELL and IDIPAZ scientists identify epigenetic alterations in CVID

Ragweed pollen can trigger strong allergic reactions

Antibodies eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News